Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)

Maisonneuve-Rosemont Hospital

Status: Completed

Conditions: Peritoneal Mesotheliomas

Treatments: Procedure: Cytoreductive surgery and HIPEC

Study type: Observational

Funder types: Other

Identifiers

NCT01812148

Maisonneuve Rosemont Hospital

12112

Details and patient eligibility

About

Review of the investigators hospital experience in cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) for peritoneal mesotheliomas, using Oxaliplatin as intraperitoneal chemotherapeutic agent.

Full description

Observation of primary outcome:

• Overall Survival
• Disease-free survival

Influencing factors that will be observe:

• Sex
• Blood loss
• Time of surgery
• Number of resection and anastomosis
• Peritoneal Index (PI score)
• Cytoreductibility (CCR score)

Enrollment: 19 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Peritoneal mesothelioma

Exclusion criteria

• Non resectable disease

Trial design

19 participants in 1 patient group

Peritoneal Mesotheliomas

Description:

Cytoreductive surgery and HIPEC

Treatment:

Procedure: Cytoreductive surgery and HIPEC